Antibody treatment of mice started 2 days after challenge with 105 B78-D14 or B16-EpCAM cells. In the experiments shown, 5 to 10 mice were included. (A) Blocking of CTLA-4 alone by HB304 has only a marginal effect on tumor killing. (B) Survival of mice after therapy with Surek alone or with Surek simultaneously delivered with HB304. (C) Moderate survival benefit of mice treated with trAb BiLu and HB304 in comparison to monotherapy in the B16-EpCAM model. Significances were determined using the logrank test.